The OncoAlert ASCO 2025 Coverage
The OncoAlert Network had the great privilege of being on site at the American Society of Clinical Oncology (ASCO) Congress 2025 in Chicago, USA. It was an incredible year for science, with major breakthroughs presented and numerous high-impact publications released in journals such as The New England Journal of Medicine, Nature, and many more.
To enhance your ASCO experience, we’re excited to share a selection of exclusive videos from the congress. For a more comprehensive overview, we invite you to register for the full #ASCO25 OncoAlert Newsletter—your go-to resource for expert insights, highlights, and key takeaways from this year’s meeting.
To enhance your ASCO experience, we’re excited to share a selection of exclusive videos from the congress. For a more comprehensive overview, we invite you to register for the full #ASCO25 OncoAlert Newsletter—your go-to resource for expert insights, highlights, and key takeaways from this year’s meeting.
|
Dr. Gil Morgan highlights breakthrough ASCO 2025 Day 1 cancer trials, including promising advances in breast, gastric, and pancreatic cancer treatments, with expert insights and a newsletter link for deeper coverage.
|
Dr. Gil Morgan highlights four key trials from ASCO25 Day 2—including breakthroughs in breast, gastric, and pancreatic cancers—offering expert insights and inviting viewers to explore more through the OncoAlert newsletter.
|
Dr. Gil Morgan recaps four game-changing ASCO25 Day 3 trials—from exercise in colon cancer to immunotherapy and precision therapy—highlighting major advances set to reshape cancer care.
|
Breast Cancer
|
Dr. Sara Tolaney presents DESTINY-Breast09 showing T-DXd + pertuzumab significantly improves PFS over standard THP in first-line HER2+ advanced breast cancer.
Dr. Angela Toss presents global data showing that BRCA1/2 mutation type impacts prognosis in young breast cancer patients, with missense variants linked to better outcomes than truncating mutations.
Patritumab deruxtecan (HER3-DXd) shows promise in treating leptomeningeal disease (LMD) from solid tumors, with new data from the TUXEDO-3 trial presented by Dr. Matthias Preusser at #ASCO25 and published in Nature Medicine.
|
Dr. Erika Hamilton presents VERITAC-2 results at #ASCO25, showing vepdegestrant significantly improves PFS over fulvestrant in ESR1-mutant ER+/HER2- advanced breast cancer. This was simultaneously published on NEJM.
Dr. Sara Tolaney presents ASCENT-04/KEYNOTE-D19 showing sacituzumab govitecan + pembrolizumab significantly improves outcomes over chemo in PD-L1+ advanced TNBC, suggesting a new standard of care.
Dr. Gaia Griguolo goes through the TUXEDO 3 and REINS trials presented in ASCO 2025
|
GU Cancer
|
Join Dr. Brian Rini and Dr. Tom Powles at ASCO 2025 as they explore the latest breakthroughs and new antibody-drug conjugates transforming bladder cancer treatment Today and what it will look like tomorrow.
Dr. Marc Machaalani presents how elevated circulating KIM-1 in renal cell carcinoma links to aggressive tumor genetics and poor prognosis, highlighting its potential as a key biomarker for personalized treatment.
Desde ASCO 2025, la Dra. Natalia Gandur presenta en un solo vistazo los avances más importantes en cáncer de próstata metastásico resistente a la castración, incluyendo nuevos tratamientos y datos clave.
|
Dr. Brian Rini and Dr. Tom Powles discuss the 9-year final results of CheckMate 214 and other IO-based combinations in mRCC at ASCO 2025, highlighting key takeaways and the future of immunotherapy in kidney cancer.
Dr. Miguel Zugman reveals that adding the live biotherapeutic CBM588 to nivolumab/ipilimumab significantly improves treatment response and survival in metastatic renal cell carcinoma patients.
La Dra. Natalia Gandur presenta desde ASCO 2025 los avances más destacados en cáncer de próstata, incluyendo nuevas terapias y datos clave para la práctica clínica.
|
Lung Oncology
|
Could the clock be your next cancer treatment tool? Dr. Hidehito Horinouchi unpacks compelling real-world data from ASCO 2025 showing that timing immunotherapy earlier in the day may significantly improve outcomes in advanced NSCLC.
|
Could tarlatamab redefine second-line treatment in relapsed small cell lung cancer? Dr. Hidehito Horinouchi breaks down the pivotal Phase 3 DeLLphi-304 trial, exploring this DLL3-targeting BiTE immunotherapy versus standard care—only at ASCO 2025.
|
Final 5-year results from CheckMate 816 confirm that neoadjuvant nivolumab + chemotherapy delivers a groundbreaking OS benefit in resectable NSCLC, cutting risk of death by nearly 90% in pCR and setting a new standard in early-stage lung cancer treatment.
|